RaÃºl J Andrade

List of Publications by Year
in descending order

190	13,652	28274	23533
papers	citations	55 h-index	111 g-index

210	210	210	9373
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. Gastroenterology, 2005, 129, 512-521.	1.3	847
2	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 2005, 128, 636-641.	1.3	699
3	EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology, 2019, 70, 1222-1261.	3.7	629
4	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. Gastroenterology, 2005, 129, 512-521.	1.3	595
5	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology, 2011, 141, 338-347.	1.3	412
6	Drug-induced liver injury. Nature Reviews Disease Primers, 2019, 5, 58.	30.5	409
7	Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut, 2017, 66, 1154-1164.	12.1	370
8	Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. Gastroenterology, 2006, 131, 451-460.	1.3	361
9	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology, 2019, 156, 2230-2241.e11.	1.3	346
10	Drug-induced liver injury: Interactions between drug properties and host factors. Journal of Hepatology, 2015, 63, 503-514.	3.7	319
11	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54, 931-939.	7.3	279
12	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology, 2006, 44, 1581-1588.	7.3	267
13	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology, 2009, 49, 2001-2009.	7.3	266
14	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. Gastroenterology, 2014, 147, 109-118.e5.	1.3	248
15	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology, 2005, 41, 779-789.	7.3	245
16	Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology, 2001, 33, 123-130.	7.3	240
17	GlutathioneS-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology, 2008, 48, 588-596.	7.3	181
18	Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. Journal of Hepatology, 2008, 48, 721-727.	3.7	175

#	Article	IF	Citations
19	Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	1.3	174
20	Candidate biomarkers for the diagnosis and prognosis of drugâ€induced liver injury: An international collaborative effort. Hepatology, 2019, 69, 760-773.	7.3	166
21	Causality assessment methods in drug induced liver injury: Strengths and weaknesses. Journal of Hepatology, 2011, 55, 683-691.	3.7	164
22	Hepatic safety of antibiotics used in primary care. Journal of Antimicrobial Chemotherapy, 2011, 66, 1431-1446.	3.0	154
23	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. Hepatology, 2006, 44, 850-856.	7.3	143
24	Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBaseâ„¢. Drug Safety, 2010, 33, 503-522.	3.2	142
25	Treatment of insulin resistance with metformin in naÃ¯ve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology, 2009, 50, 1702-1708.	7.3	136
26	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology, 2004, 39, 1603-1612.	7.3	134
27	Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. World Journal of Gastroenterology, 2007, 13, 329.	3.3	134
28	Drug induced liver injury: an update. Archives of Toxicology, 2020, 94, 3381-3407.	4.2	125
29	Scientific opinion on the safety of green tea catechins. EFSA Journal, 2018, 16, e05239.	1.8	118
30	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. Journal of Hepatology, 2016, 65, 532-542.	3.7	115
31	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. International Journal of Molecular Sciences, 2016, 17, 537.	4.1	114
32	Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World Journal of Hepatology, 2014, 6, 160.	2.0	105
33	Development and Validation of Hepamet Fibrosis Scoring Systemâ€“A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2020, 18, 216-225.e5.	4.4	104
34	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology, 2010, 52, 303-312.	7.3	97
35	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. Gastroenterology, 2019, 156, 1707-1716.e2.	1.3	97
36	Trovafloxacin-Induced Acute Hepatitis. Clinical Infectious Diseases, 2000, 30, 400-401.	5.8	91

#	Article	IF	Citations
37	Drug-induced liver injury: insights from genetic studies. Pharmacogenomics, 2009, 10, 1467-1487.	1.3	90
38	Mechanisms of drug-induced liver injury. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 286-292.	2.3	86
39	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. Gastroenterology, 2019, 157, 552-568.	1.3	85
40	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. Clinical Gastroenterology and Hepatology, 2018, 16, 1495-1502.	4.4	83
41	HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. PLoS ONE, 2013, 8, e68111.	2.5	81
42	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3ÂInfectionÂand Cirrhosis. Gastroenterology, 2018, 155, 1120-1127.e4.	1.3	76
43	Antidepressant-induced hepatotoxicity. Expert Opinion on Drug Safety, 2003, 2, 249-262.	2.4	75
44	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 31-41.	8.1	75
45	Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. European Journal of Clinical Pharmacology, 2002, 58, 435-440.	1.9	72
46	Analysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcome. Journal of Hepatology, 2008, 49, 107-114.	3.7	72
47	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. Journal of Hepatology, 2021, 75, 86-97.	3.7	72
48	Causality assessment in drug-induced hepatotoxicity. Expert Opinion on Drug Safety, 2004, 3, 329-344.	2.4	70
49	Pharmacogenomics in Drug Induced Liver Injury. Current Drug Metabolism, 2009, 10, 956-970.	1.2	70
50	The effects of metabolic status on nonâ€alcoholic fatty liver diseaseâ€related outcomes, beyond the presence of obesity. Alimentary Pharmacology and Therapeutics, 2018, 48, 1260-1270.	3.7	70
51	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. International Journal of Molecular Sciences, 2016, 17, 714.	4.1	69
52	Assessment of drugâ€induced liver injury in clinical practice. Fundamental and Clinical Pharmacology, 2008, 22, 141-158.	1.9	66
53	Advanced preclinical models for evaluation of drug-induced liver injury â€“ consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. Journal of Hepatology, 2021, 75, 935-959.	3.7	66
54	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants, 2021, 10, 390.	5.1	64

#	Article	IF	Citations
55	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. International Journal of Molecular Sciences, 2016, 17, 313.	4.1	63
56	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology, 2020, 73, 17-25.	3.7	59
57	Drugâ€induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clinical Pharmacology and Therapeutics, 2019, 106, 245-253.	4.7	58
58	Acute liver injury associated with the use of ebrotidine, a new H 2 -receptor antagonist. Journal of Hepatology, 1999, 31, 641-646.	3.7	55
59	Biomarkers in DILI: One More Step Forward. Frontiers in Pharmacology, 2016, 7, 267.	3.5	52
60	Shared Genetic Risk Factors Across Carbamazepineâ€induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	4.7	52
61	A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology, 2022, 76, 18-31.	7.3	52
62	Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology, 2008, 47, 810-816.	7.3	51
63	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 817-828.	3.3	48
64	Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opinion on Drug Safety, 2009, 8, 709-714.	2.4	47
65	The value of serum aspartate aminotransferase and gammaâ€glutamyl transpetidase as biomarkers in hepatotoxicity. Liver International, 2015, 35, 2474-2482.	3.9	47
66	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. European Journal of Gastroenterology and Hepatology, 2002, 14, 887-890.	1.6	45
67	Metformin-Induced Hepatotoxicity. Diabetes Care, 2012, 35, e21-e21.	8.6	45
68	Drug-induced liver injury in older people. The Lancet Gastroenterology and Hepatology, 2020, 5, 862-874.	8.1	42
69	HLA-C and KIR Genes in Hepatitis C Virus Infection. Human Immunology, 2005, 66, 1106-1109.	2.4	41
70	Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroidâ€responsive hepatitis: report of 22 cases. Liver International, 2016, 36, 302-310.	3.9	39
71	Acute liver failure after treatment with nefazodone. Digestive Diseases and Sciences, 1999, 44, 2577-2579.	2.3	38
72	Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drugâ€induced liver injury. Liver International, 2013, 33, 1378-1385.	3.9	38

#	Article	IF	Citations
73	The pro-/anti-inflammatory effects of different fatty acids on visceral adipocytes are partially mediated by GPR120. European Journal of Nutrition, 2017, 56, 1743-1752.	3.9	35
74	Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. Current Drug Safety, 2010, 5, 212-222.	0.6	34
75	Continuous reporting of new cases in Spain supports the relationship between HerbalifeÂ® products and liver injury. Pharmacoepidemiology and Drug Safety, 2011, 20, 1080-1087.	1.9	34
76	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. International Journal of Molecular Sciences, 2021, 22, 4557.	4.1	34
77	Letters to the Editor. Journal of Hepatology, 2000, 32, 174.	3.7	33
78	Drug-Induced Liver Injury: Expanding Our Knowledge by Enlarging Population Analysis With Prospective and Scoring Causality Assessment. Gastroenterology, 2015, 148, 1271-1273.	1.3	33
79	Hepatic Damage by Natural Remedies. Seminars in Liver Disease, 2018, 38, 021-040.	3.6	33
80	Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. Journal of Hepatology, 1995, 22, 189-196.	3.7	32
81	Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials. Drug Safety, 2014, 37, 19-31.	3.2	32
82	Systematic review: ibuprofenâ€induced liver injury. Alimentary Pharmacology and Therapeutics, 2020, 51, 603-611.	3.7	32
83	Drug-Induced Liver Injury Due to Antimicrobials, Central Nervous System Agents, and Nonsteroidal Anti-Inflammatory Drugs. Seminars in Liver Disease, 2014, 34, 145-161.	3.6	31
84	Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. Journal of Hepatology, 2015, 62, 751-752.	3.7	31
85	Creating an effective clinical registry for rare diseases. United European Gastroenterology Journal, 2016, 4, 333-338.	3.8	31
86	Drug-induced liver injury: a safety review. Expert Opinion on Drug Safety, 2018, 17, 795-804.	2.4	31
87	Genetic Risk Factors in Drugâ€Induced Liver Injury Due to Isoniazidâ€Containing Antituberculosis Drug Regimens. Clinical Pharmacology and Therapeutics, 2021, 109, 1125-1135.	4.7	31
88	Drug use for non-hepatic associated conditions in patients with liver cirrhosis. European Journal of Clinical Pharmacology, 2003, 59, 71-76.	1.9	30
89	Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. Drug Safety, 2016, 39, 925-943.	3.2	30
90	Chronic liver injury induced by drugs and toxins. Journal of Digestive Diseases, 2018, 19, 514-521.	1.5	30

#	Article	IF	Citations
91	Diagnostic and prognostic assessment of suspected drugâ€induced liver injury in clinical practice. Liver International, 2020, 40, 6-17.	3.9	30
92	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. United European Gastroenterology Journal, 2019, 7, 825-837.	3.8	29
93	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacological Research, 2021, 164, 105404.	7.1	29
94	Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. Pharmacological Research, 2022, 182, 106348.	7.1	29
95	A morphological method for ammonia detection in liver. PLoS ONE, 2017, 12, e0173914.	2.5	28
96	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Annals of Hepatology, 2014, 13, 231-239.	1.5	27
97	Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. Acta Pharmaceutica Sinica B, 2021, 11, 3685-3726.	12.0	27
98	Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review. Current Drug Safety, 2007, 2, 97-112.	0.6	26
99	Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clinical Therapeutics, 2009, 31, 1014-1019.	2.5	26
100	Hepatotoxicity induced by coxibs: how concerned should we be?. Expert Opinion on Drug Safety, 2016, 15, 1463-1475.	2.4	26
101	Benzylpenicillin-Induced Prolonged Cholestasis. Annals of Pharmacotherapy, 2001, 35, 783-784.	1.9	25
102	Oxidized lowâ€density lipoprotein antibodies/highâ€density lipoprotein cholesterol ratio is linked to advanced nonâ€alcoholic fatty liver disease lean patients. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1611-1618.	2.8	25
103	Elevated levels of circulating CDH5 and FABP1 in association with human drugâ€induced liver injury. Liver International, 2017, 37, 132-140.	3.9	25
104	Drug, Herb, and Dietary Supplement Hepatotoxicity. International Journal of Molecular Sciences, 2016, 17, 1488.	4.1	24
105	Sertraline Hepatotoxicity: Report of a Case and Review of the Literature. Digestive Diseases and Sciences, 2010, 55, 1806-1807.	2.3	23
106	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. Journal of Hepatology, 2021, 75, 333-341.	3.7	23
107	Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 153-169.	3.3	22
108	Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. American Journal of Gastroenterology, 2004, 99, 2150-2157.	0.4	21

#	Article	IF	Citations
109	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. Pharmacogenetics and Genomics, 2016, 26, 414-422.	1.5	21
110	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). Clinical Liver Disease, 2019, 13, 51-57.	2.1	21
111	Genetic Predisposition to Drug-Induced Liver Injury. Clinics in Liver Disease, 2020, 24, 11-23.	2.1	21
112	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. Clinical Gastroenterology and Hepatology, 2022, 20, e548-e563.	4.4	21
113	Long-term sequelae of drug-induced liver injury. Journal of Hepatology, 2022, 76, 435-445.	3.7	21
114	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	3.7	21
115	Norfloxacin-Induced Cholestatic Jaundice. American Journal of Gastroenterology, 1998, 93, 2309-2311.	0.4	20
116	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. Seminars in Liver Disease, 2019, 39, 381-394.	3.6	20
117	Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2000, 14, 929-935.	3.7	19
118	Chronic Hepatitis C, Ibuprofen, and Liver Damage. American Journal of Gastroenterology, 2002, 97, 1854-1855.	0.4	19
119	Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. Annals of Pharmacotherapy, 2004, 38, 1540-1541.	1.9	19
120	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Safety, 2021, 44, 133-165.	3.2	19
121	Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. PLoS ONE, 2014, 9, e94675.	2.5	19
122	Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Review of Clinical Pharmacology, 2008, 1, 261-276.	3.1	18
123	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. Clinical Gastroenterology and Hepatology, 2018, 16, 292-294.	4.4	18
124	Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. World Journal of Gastroenterology, 2006, 12, 5244-6.	3.3	18
125	N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. Frontiers in Pharmacology, 2022, 13, .	3.5	18
126	Severe idiosyncratic acute hepatic injury caused by paracetamol. Journal of Hepatology, 1998, 28, 1078.	3.7	17

#	Article	IF	Citations
127	Incidence of and Factors Associated with Hepatocellular Carcinoma among Hepatitis C Virus and Human Immunodeficiency Virus Coinfected Patients with Decompensated Cirrhosis. AIDS Research and Human Retroviruses, 2006, 22, 1236-1241.	1.1	17
128	â€œDrug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challengeâ€. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 589-593.	3.3	17
129	The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. European Journal of Gastroenterology and Hepatology, 2005, 17, 59-63.	1.6	16
130	Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge. Digestive Diseases and Sciences, 2011, 56, 2501-2503.	2.3	16
131	Clinical Characteristics and Outcome of Drugâ€Induced Liver Injury in the Older Patients: From the Youngâ€Old to the Oldestâ€Old. Clinical Pharmacology and Therapeutics, 2021, 109, 1147-1158.	4.7	16
132	Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid. Digestive Diseases and Sciences, 2001, 46, 1416-1419.	2.3	15
133	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. Journal of Hepatology, 2018, 68, 940-948.	3.7	15
134	Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. Drug Safety, 2021, 44, 619-634.	3.2	15
135	Lymphocyte Profile and Immune Checkpoint Expression in Drugâ€Induced Liver Injury: An Immunophenotyping Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1604-1612.	4.7	15
136	Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?. Gastroenterology Report, 2022, 10, goac014.	1.3	15
137	Setting up criteria for drugâ€induced autoimmuneâ€like hepatitis through a systematic analysis of published reports. Hepatology Communications, 2022, 6, 1895-1909.	4.3	15
138	Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs. World Journal of Gastroenterology, 2006, 12, 5078.	3.3	14
139	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. PLoS ONE, 2017, 12, e0189436.	2.5	13
140	Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. Phytotherapy Research, 2021, 35, 6-19.	5.8	13
141	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsyâ€proven nonalcoholic fatty liver disease subjects. Liver International, 2021, 41, 2076-2086.	3.9	13
142	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. Current Pharmaceutical Design, 2019, 25, 3855-3871.	1.9	13
143	Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. Frontiers in Genetics, 2012, 3, 253.	2.3	12
144	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Annals of Hepatology, 2014, 13, 356-63.	1.5	12

#	Article	IF	Citations
145	Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology. Frontiers in Pharmacology, 2012, 3, 2.	3.5	11
146	The influence of drug properties and host factors on delayed onset of symptoms in drugâ€induced liver injury. Liver International, 2018, 39, 401-410.	3.9	10
147	Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. Frontiers in Genetics, 2019, 10, 134.	2.3	10
148	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drugâ€Induced Liver Injury in the Spanish DILI Registry. Liver International, 2020, 41, 1523-1531.	3.9	10
149	Drugâ€Induced Liver Injury After Liver Transplantation. Liver Transplantation, 2020, 26, 1167-1176.	2.4	10
150	Drugâ€induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. Liver International, 2021, 41, 2671-2680.	3.9	9
151	Acute Fulminant Hepatitis After Treatment With Rabeprazole and Terbinafine: Is Rabeprazole the Culprit?. Archives of Internal Medicine, 2002, 162, 360-361.	3.8	9
152	Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. Revista Espanola De Enfermedades Digestivas, 2012, 104, 282-283.	0.3	9
153	ÂBuilding a Spanish-Latin American network on drug induced liver injury: much to get from a joint collaborative initiative. Annals of Hepatology, 2012, 11, 544-9.	1.5	9
154	Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Annals of Hepatology, 2014, 13, 231-9.	1.5	9
155	Characterizing Drug-Induced Liver Injury With Autoimmune Features. Clinical Gastroenterology and Hepatology, 2016, 14, 1844-1845.	4.4	8
156	Protective role of câ€Jun Nâ€terminal kinaseâ€2 (JNK2) in ibuprofenâ€induced acute liver injury. Journal of Pathology, 2019, 247, 110-122.	4.5	8
157	Beneficial effect of ursodeoxycholic acid in patients with acylâ€CoA oxidase 2 (ACOX2) deficiencyâ€“associated hypertransaminasemia. Hepatology, 2022, 76, 1259-1274.	7.3	8
158	Acute leukemia after infliximab therapy. American Journal of Gastroenterology, 2003, 98, 2577.	0.4	7
159	Serious liver injury induced by Nimesulide: an international collaborative study. Archives of Toxicology, 2021, 95, 1475-1487.	4.2	7
160	Lansoprazole-Induced Hepatic Dysfunction. Annals of Pharmacotherapy, 2003, 37, 1731-1731.	1.9	6
161	Safety of treating acute liver injury and failure. Expert Opinion on Drug Safety, 2022, 21, 191-203.	2.4	6
162	Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers. Drug and Alcohol Dependence, 1990, 26, 161-168.	3.2	5

#	Article	IF	Citations
163	Plasma Ribavirin Trough Concentrations During Treatment of Chronic Hepatitis C in Genotype-1 Patients. Journal of Clinical Gastroenterology, 2012, 46, 328-333.	2.2	5
164	Reducing Risk of Severe Liver Injury in Patients Treated With Isoniazid. Clinical Gastroenterology and Hepatology, 2015, 13, 1683-1685.	4.4	4
165	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r Â± dasabuvir Â± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS ONE, 2019, 14, e0225061.	2.5	4
166	Statins: Hepatic Disease and Hepatotoxicity Risk. The Open Gastroenterology Journal, 2008, 2, 18-23.	0.1	4
167	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. Biomedicines, 2022, 10, 55.	3.2	4
168	Portal hypertension and refractory ascites associated with multicentric Castleman's disease. Digestive Diseases and Sciences, 2000, 45, 697-702.	2.3	3
169	Unusual duodenal duplication cyst associated with partial gastric diverticulum in a middle-aged woman: are they congenital or acquired?. Digestive Diseases and Sciences, 2002, 47, 304-308.	2.3	3
170	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanateâ€“Induced Liver Injury in Spanish Patients. Frontiers in Pharmacology, 2016, 7, 280.	3.5	3
171	A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. American Journal of Gastroenterology, 2017, 112, 384-385.	0.4	3
172	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. Current Hepatology Reports, 2017, 16, 286-292.	0.9	3
173	Drugâ€induced liver and skin reactions: In need of a consensus definition. Hepatology, 2017, 65, 391-391.	7.3	3
174	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machineÂlearning approach. Archives of Toxicology, 2021, 95, 1793-1803.	4.2	3
175	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. Journal of Clinical Medicine, 2021, 10, 5317.	2.4	3
176	Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Antiviral Therapy, 2006, 11, 491-8.	1.0	3
177	Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. Antioxidants, 2022, 11, 897.	5.1	3
178	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. Methods in Pharmacology and Toxicology, 2018, , 477-496.	0.2	2
179	Landscape of Liver Injury From Herbal and Dietary Supplements in Europe, Latin America, and Asia. Clinical Liver Disease, 2019, 14, 49-50.	2.1	2
180	Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naÃ¯ve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study. GastroenterologÃa Y HepatologÃa, 2022, 45, 342-349.	0.5	2

#	Article	IF	Citations
181	Corrigendum to â€œAnalysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcomeâ€•[J Hepatol 49 (2008) 107â€“114]. Journal of Hepatology, 2009, 50, 636.	3.7	1
182	S1873 The use of Liver Biopsy Evaluation in Determination of Autoimmune Hepatitis vs. Drug-Induced Liver Injury. Gastroenterology, 2010, 138, S-807.	1.3	1
183	Causality Assessment. , 2013, , 287-302.		1
184	P041â€…Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .		1
185	Reply:. Hepatology, 2009, 49, 1777-1779.	7.3	0
186	Metformin improves sustained virologic response in difficult-to-cure hepatitis C: More questions than answers. Hepatology, 2010, 51, NA-NA.	7.3	0
187	Reply. Gastroenterology, 2014, 147, 1442.	1.3	0
188	Reply. Gastroenterology, 2015, 148, 452-453.	1.3	0
189	Reply letter to â€œEditorial: bodybuilders bewareâ€• Alimentary Pharmacology and Therapeutics, 2019, 50, 473-473.	3.7	0
190	Herbalâ€induced liver injury: The price to pay for a healthier life?. Liver International, 2019, 39, 257-259.	3.9	0